Robecosam AG boosted its stake in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 30.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 210,202 shares of the medical instruments supplier’s stock after buying an additional 49,666 shares during the quarter. Robecosam AG owned approximately 0.09% of DENTSPLY SIRONA worth $13,964,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC lifted its stake in DENTSPLY SIRONA by 41.4% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,389,010 shares of the medical instruments supplier’s stock valued at $83,076,000 after buying an additional 406,654 shares in the last quarter. California Public Employees Retirement System lifted its stake in DENTSPLY SIRONA by 2.2% in the 3rd quarter. California Public Employees Retirement System now owns 499,526 shares of the medical instruments supplier’s stock valued at $29,877,000 after buying an additional 10,828 shares in the last quarter. Victory Capital Management Inc. lifted its stake in DENTSPLY SIRONA by 22,502.5% in the 4th quarter. Victory Capital Management Inc. now owns 855,955 shares of the medical instruments supplier’s stock valued at $56,348,000 after buying an additional 852,168 shares in the last quarter. Wells Fargo & Company MN lifted its stake in DENTSPLY SIRONA by 3.1% in the 3rd quarter. Wells Fargo & Company MN now owns 882,002 shares of the medical instruments supplier’s stock valued at $52,752,000 after buying an additional 26,125 shares in the last quarter. Finally, Amica Mutual Insurance Co. purchased a new position in DENTSPLY SIRONA in the 3rd quarter valued at about $669,000. 96.80% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Eric Brandt sold 6,409 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $68.04, for a total value of $436,068.36. Following the completion of the sale, the director now owns 12,073 shares in the company, valued at approximately $821,446.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.99% of the stock is currently owned by company insiders.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.01. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.06 billion. DENTSPLY SIRONA had a negative net margin of 39.39% and a positive return on equity of 8.35%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.67 EPS. analysts forecast that DENTSPLY SIRONA Inc will post 2.74 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend is Wednesday, March 28th. DENTSPLY SIRONA’s payout ratio is presently -5.09%.
A number of brokerages recently weighed in on XRAY. HC Wainwright lowered shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target on the stock. in a research note on Thursday, November 30th. Deutsche Bank assumed coverage on shares of DENTSPLY SIRONA in a research note on Friday, December 8th. They issued a “buy” rating and a $81.00 price target on the stock. BidaskClub lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Zacks Investment Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. Finally, JPMorgan Chase & Co. raised shares of DENTSPLY SIRONA from a “neutral” rating to an “overweight” rating and set a $75.00 target price on the stock in a research note on Wednesday, December 13th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $67.43.
WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/12/robecosam-ag-raises-position-in-dentsply-sirona-inc-xray.html.
DENTSPLY SIRONA Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.